Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-3: ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment for metastatic squamous non-small cell lung cancer
CTR20232457Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Oct 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in Pulmonary squamous cell carcinoma, sponsored by Akeso, Inc.. Started Oct 2023; status: active.
02
Drugs
ivonescimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20232457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232457.